Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off

7. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders In Q3 2024: 106

Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant that is at the heart of the weight loss drug market. It’s also one of Cramer’s favorite stocks as he has mentioned the firm multiple times on his show this year. In his recent appearance, Cramer stressed that Eli Lilly and Company (NYSE:LLY)’s scripts for its weight loss treatments were improving. He believes that scripts are key to evaluating drug companies, as other factors such as trials paint an incomplete picture. Cramer has also advised viewers to not be spooked by recent Eli Lilly and Company (NYSE:LLY) share price dips. Here are his latest remarks:

“[nvo new results stock down] Okay, one and a half, it’s early. Remember it’s a one half trial. Now, you cane make these, you can finagle Lilly versus Novo. It’s hard, very hard to do actual comparisons because some are by forty eight weeks, some are shorter weeks. Some are bigger. . . what really matters? Boom, Eli Lilly’s scripts are way up. And if you’re looking at the fourth quarter, remember fourth quarter was a disappointment. David Ricks came on Mad Money, he came on our show. What did he say? He said we botched the launch. This is the beginning. Wolfe puts out the scripts, the numbers for Lilly were really good. And that’s what I’ve been waiting for. We can do this head to head of the phase one, the half. Forget that. Novo’s down so much, anything they put out . . .and this thing causes, you know it like makes you feel better. It wouldn’t matter. What matters is that Mounjaro and Zepbound weekly scripts are finally, finally doing good. And they have been not good. . . .”

“Lilly versus Novo this morning. Not one. Looked at every single data test that there is. Not one.”

“You can’t compare an eighteen week to a thirty six week and there’s just lots of different guess work. And I prefer, I spoke with David Ricks last week, you gotta be really careful. What really matters is scripts. And that’s why, that’s why Lilly is up today. It’s about the scripts, not about the pill. And the scripts are now turning up after, really, a disastrous fourth quarter for Lilly. Disastrous.”